L-carnitine supplementation in the therapy of canine dilated cardiomyopathy.
In evaluating any novel therapeutic agent or intervention, the clinician must question the need for as well as the efficacy and safety of the proposed therapy. In an attempt to address these critical questions with regard to the role of L-carnitine supplementation in the therapy of dilated cardiomyopathy, this article reviews the currently available scientific evidence and clinical experience regarding carnitine metabolism and supplementation in the dog.